Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05778838Phase 2Completed

Midodrine Effect on the Mortality Rates in Septic Shock Patients

Role: lead

NCT06265077Phase 1Completed

Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients

Role: lead

NCT05447520Phase 2Completed

Montelukast Use in Rheumatoid Arthritis

Role: lead

NCT05402553Phase 1Unknown

The Efficacy of Adjunctive Use of Ondansetron in Patients With Sepsis and Septic Shock

Role: lead

All 4 trials loaded